Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

M.D. Anderson Cancer Center

Reviewed by TrialFinderData Editorial Team · Updated

48 clinical trials · 48 recruiting · OTHER

M.D. Anderson Cancer Center has 48 clinical trials registered on ClinicalTrials.gov, with 48 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About M.D. Anderson Cancer Center\'s Trial Portfolio

M.D. Anderson Cancer Center is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

48 of M.D. Anderson Cancer Center's 48 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

M.D. Anderson Cancer Center's research footprint spans Hematopoietic and Lymphoid Cell Neoplasm (4 trials), Malignant Solid Neoplasm (4), and Lung Carcinoma (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Phase 2 is the largest single phase in M.D. Anderson Cancer Center's portfolio at 35% of registered trials. The full phase breakdown appears in the sidebar.

Trials by M.D. Anderson Cancer Center

RECRUITINGPhase 1NCT06959537

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) +...

The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 241 location
Breast Cancer
RECRUITINGNCT03422302

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients...

This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in patients undergoing...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 301 location
Lung CarcinomaMalignant Respiratory Tract NeoplasmMetastatic Malignant Neoplasm in the Lung
RECRUITINGPhase 2NCT07133425

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 291 location
Non-Small Cell Lung CancerICI-refractory
RECRUITINGNCT06909201

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for...

The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 701 location
Lung Cancer
RECRUITINGNCT05054413

Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method

This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 101 location
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
RECRUITINGPhase 2NCT06959550

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic...

The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 901 location
Metastatic Colorectal Cancer
RECRUITINGPhase 2NCT06617858

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 151 location
Colorectal Cancer
RECRUITINGNCT04666727

Role of Diet on the Microbiome of the Digestive System

This study is to learn more about how diet affects the microbiome (bacteria and microorganisms) of the digestive system. Researchers want to learn if this, in turn, has an effect...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 301 location
Colorectal Carcinoma
RECRUITINGPhase 1NCT05873699

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts...

To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 201 location
Pancreatic Cyst
RECRUITINGPhase 1NCT05039801

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 541 location
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35
RECRUITINGNCT04693377

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME...

This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
Castration-Resistant Prostate CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the Bone+15
RECRUITINGNCT06887205

Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study

To learn if LBP can help to prevent lymphedema when it is performed at the time of surgery rather than after a patient has already developed the disease.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 201 location
Lymphatic ReconstructionLymphadenectomy
RECRUITINGPhase 2NCT03136146

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic...

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 421 location
Recurrent Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt Leukemia+8
RECRUITINGPhase 2NCT01515527

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or...

The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1601 location
Leukemia
RECRUITINGPhase 2NCT06698822

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma...

To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 201 location
Cutaneous T-Cell Lymphoma
RECRUITINGPhase 2NCT06213311

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large...

To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
B Cell Lymphoma
RECRUITINGPhase 3NCT03741673

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1801 location
Malignant NeoplasmMetastatic Malignant Neoplasm in the Brain
RECRUITINGNCT03458676

Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

The goal of this clinical research study is to learn if using advanced magnetic resonance imaging (AMRI) will improve the targeting of brain tumor needle biopsies compared to the...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 621 location
Brain Lesion
RECRUITINGNCT07186556

Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of...

The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 751 location
CancerFatigueBrain Tumor Adult
RECRUITINGPhase 2NCT05673928

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid...

To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 301 location
Metastatic Solid TumorBrain Metastases
RECRUITINGPhase 1NCT07401875

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The

Sponsor: M.D. Anderson Cancer CenterEnrolling: 351 location
Phase 1bHC-7366SHARK+1
RECRUITINGPhase 1 / Phase 2NCT05703854

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy...

To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma....

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
Advanced Renal Cell CarcinomaAdvanced MesotheliomaAdvanced Osteosarcoma
RECRUITINGPhase 2NCT06940518

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
IvonescimabClear Cell Renal Carcinoma
RECRUITINGPhase 2NCT06053658

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 486 locations
Renal Cell Carcinoma
RECRUITINGPhase 1NCT05092373

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel...

This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 431 location
Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube Carcinoma+71
RECRUITINGPhase 1 / Phase 2NCT06434350

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 411 location
Advanced Bladder Cancer
RECRUITINGNCT06507878

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions-...

The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 4591 location
Thyroid Cancer
RECRUITINGNCT07140757

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
Low RiskPapillary Thyroid CancerRadiofrequency Ablation
RECRUITINGNCT07226804

Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 301 location
Thyroid NodulesPulsed Field Ablation
RECRUITINGPhase 1NCT04589624

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other...

This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 421 location
Thyroid Gland Carcinoma

Showing 30 of 48 trials. The remainder are accessible through individual condition pages or directly on ClinicalTrials.gov.

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does M.D. Anderson Cancer Center have on ClinicalTrials.gov?

M.D. Anderson Cancer Center has 48 clinical trials registered on the federal ClinicalTrials.gov registry, of which 48 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does M.D. Anderson Cancer Center study?

M.D. Anderson Cancer Center's registered trials cover 20 conditions on ClinicalTrials.gov, led by Hematopoietic and Lymphoid Cell Neoplasm (4 trials), Malignant Solid Neoplasm (4 trials), Lung Carcinoma (2 trials), Advanced Endometrial Carcinoma (2 trials), Stage Iii Ovarian Cancer Ajcc v8 (2 trials). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a M.D. Anderson Cancer Center clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 48 trials tracked for M.D. Anderson Cancer Center.